ISDA

Deposition Date 2021-01-29

Release Date 2021-03-17

Last Version Date 2023-10-18

Entry Detail

PDB ID:

7LJE

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

Discovery of Spirohydantoins as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.61 Å

R-Value Free:

0.26

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Histone acetyltransferase p300
Gene (Uniprot):EP300
Chain IDs:A, B, C, D
Chain Length:348
Number of Molecules:4
Biological Source:Homo sapiens

UniProt ID:Q09472 Pfam ID:PF08214 EC:2.3.1.48

Ligand Molecules

Y2P

Primary Citation

Discovery of spirohydantoins as selective, orally bioavailable inhibitors of p300/CBP histone acetyltransferases.

Ji, Z, Clark, R.F, Bhat, V, Matthew Hansen, T, Lasko, L.M, Bromberg, K.D, Manaves, V, Algire, M, Martin, R, Qiu, W, Torrent, M, Jakob, C.G, Liu, H, Cole, P.A, Marmorstein, R, Kesicki, E.A, Lai, A, Michaelides, M.R.Show

Bioorg.Med.Chem.Lett. 39 127854 127854 (2021)

PMID: 33631370 DOI: 10.1016/j.bmcl.2021.127854

Abstact

p300 and CREB-binding protein (CBP) are essential for a multitude of cellular processes. Dysregulation of p300/CBP histone acetyltransferase activity is linked to a broad spectrum of human diseases including cancers. A novel drug-like spirohydantoin (21) has been discovered as a selective orally bioavailable inhibitor of p300/CBP histone acetyltransferase. Lead compound 21 is more potent than the first-in-class lead A-485 in both enzymatic and cellular assays and lacks the off-target inhibition of dopamine and serotonin transporters, that was observed with A-485.

Legend

Protein

Chemical

Disease

Primary Citation of related structures